Followers | 31 |
Posts | 2649 |
Boards Moderated | 0 |
Alias Born | 10/28/2013 |
Saturday, April 19, 2014 11:42:19 PM
What is meaningful is that the trial can continue while you are asking the FDA about early termination. When I suggested such in the past I was shot down. Someone said the trial had to halt in that circumstance.
But they also argued that the DMC can not be petitioning for early termination without involving NW. That it doesn't work that way. I do wonder if they could walk the line and leave just Les Goldman and Linda Powers out of the loop. Seems unlikely. Seems more likely they would be asking for a clarification of some sort from the FDA.
I do have one possible explanation for why they would talk about expanding (not necessarily extending as you point out) the trial:
I believe Germany will only be gathering data for the eventual PEI approval (or not). I believe that they will not have a placebo and will therefore not be contributing, as had been planned, to the US/FDA trial. While expansion in Europe might work to fill the gap, it is more straightforward to expand in the US, because other European countries might fall in line with the German policy. Certainly the UK. That expansion in the US will have to start very soon if they do not get an early approval. In order to explain any reports of such US expansion activity... they say, "We are considering expanding the trial." when in fact... they are just moving the US/FDA trial back to being 100% US.
All speculation, but this makes the most sense to me.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM